Emmanuel Dela Cruz, OD
Optometrist · Mountain View
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 6
- 2 carriers
- Office
- 1
Offices
1 location
Plans that list them
6 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Cruz’s office at (650) 961-2926 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
6 of 6 plans
| Central Health Classic Care Plan III (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Dual Access Plan (HMO D-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Embrace Care Plan (HMO C-SNP) | Central Health Medicare Plan | Listed, may be out of date | Sep 15, 2025 |
| Central Health Embrace Choice Plan (HMO C-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Valor Care Plan (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| AARP Medicare Advantage from UHC CA-10 (HMO-POS) | UnitedHealthcare | Listed, may be out of date | Jun 10, 2026 |
California Medical Board record
Licence C13964 · Cancelled
Licence status: Cancelled · since 1952 · Washington University School of Medicine.
License has been voluntarily canceled, or the license has been expired for at least five years and has not been renewed. No practice is permitted.
Matched on the licence number without its letter prefix; check the name before relying on it.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Drugs they prescribed that Part D paid
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their 12 Part D prescriptions in 2020. Too few prescriptions to judge: with under about 50 a year, a handful of patients can swing this share.
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
Year by year
| 2020 | 12 | None | 0% (0) | None | $194 |
| 2018 | 192 | 89 | 0% (0) | 50% | $23,898 |
| 2017 | 1,152 | 318 | 0% (0) | 49% | $140,400 |
| 2016 | 725 | 278 | 0% (0) | 42% | $74,663 |
| 2015 | 358 | 140 | 0% (0) | 42% | $32,643 |
| 2014 | 52 | 42 | 0% (0) | 31% | $2,190 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2018: 4 drugs
| Lumigan | 32 | $10,515 | $329 |
| Simbrinza | 18 | $3,009 | $167 |
| Latanoprost | 32 | $786 | $25 |
| Erythromycin | 51 | $616 | $12 |
2017: 13 drugs
| Lumigan | 186 | $59,889 | $322 |
| Travatan Z | 53 | $14,315 | $270 |
| Simbrinza | 61 | $10,719 | $176 |
| Combigan | 37 | $8,892 | $240 |
| Restasis | 11 | $7,835 | $712 |
| Tobramycin-Dexamethasone | 43 | $4,989 | $116 |
| Latanoprost | 295 | $4,909 | $17 |
| Timolol Maleate | 53 | $3,456 | $65 |
| Erythromycin | 186 | $2,130 | $11 |
| Dorzolamide-Timolol | 71 | $1,814 | $26 |
| Bacitracin | 21 | $1,803 | $86 |
| Neomycin-Polymyxin-Dexameth | 28 | $530 | $19 |
| Brimonidine | 17 | $216 | $13 |
2016: 14 drugs
| Restasis | 32 | $17,464 | $546 |
| Lumigan | 65 | $16,719 | $257 |
| Tobramycin-Dexamethasone | 67 | $7,427 | $111 |
| Travatan Z | 15 | $4,799 | $320 |
| Combigan | 14 | $4,160 | $297 |
| Simbrinza | 25 | $3,390 | $136 |
| Pataday | 14 | $2,263 | $162 |
| Latanoprost | 139 | $2,164 | $16 |
| Timolol Maleate | 34 | $2,012 | $59 |
| Erythromycin | 165 | $1,975 | $12 |
| Doxycycline Hyclate | 17 | $950 | $56 |
| Dorzolamide-Timolol | 37 | $837 | $23 |
| Prednisolone Acetate | 11 | $697 | $63 |
| Neomycin-Polymyxin-Dexameth | 31 | $546 | $18 |
2015: 8 drugs
| Patanol | 37 | $8,812 | $238 |
| Restasis | 16 | $7,393 | $462 |
| Tobramycin-Dexamethasone | 40 | $3,450 | $86 |
| Zirgan | 11 | $3,071 | $279 |
| Erythromycin | 140 | $1,888 | $13 |
| Doxycycline Hyclate | 12 | $703 | $59 |
| Latanoprost | 25 | $250 | $10 |
| Neomycin-Polymyxin-Dexameth | 12 | $142 | $12 |
2014: 1 drug
| Erythromycin | 29 | $401 | $14 |
Money from drug and device companies
$34 in 2025
| 2025 | 1 | 2 | None | $34 |
| 2024 | 3 | 3 | None | $111 |
| 2023 | 2 | 4 | None | $164 |
| 2022 | 2 | 3 | None | $142 |
| 2021 | 2 | 4 | None | $176 |
| 2020 | 4 | 4 | None | $75 |
| 2019 | 1 | 1 | None | $118 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Johnson & Johnson Vision Care | None | $34 | 2 payments
|
See all 2 published payments
| Johnson & Johnson Vision Care | Meals · 2025-10-24 | None | $18 |
| Johnson & Johnson Vision Care | Meals · 2025-05-30 | None | $17 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $111
| CooperVision | Clariti Contact Lens | $76 | 1 payment
|
| Alcon Vision | Total30 | $21 | 1 payment
|
| Johnson & Johnson Vision Care | None | $13 | 1 payment
|
2023: $164
| Johnson & Johnson Vision Care | Acuvue | $151 | 3 payments
|
| Alcon Vision | Dailies Total1 | $13 | 1 payment
|
2022: $142
| CooperVision | Myday Contact Lens | $123 | 2 payments
|
| Johnson & Johnson Vision Care | Acuvue | $19 | 1 payment
|
2021: $176
| Johnson & Johnson Vision Care | Acuvue | $164 | 3 payments
|
| CooperVision | Multiple Brands Contact Lens | $13 | 1 payment
|
2020: $75
| Carl Zeiss Meditec AG | None Specified | $19 | 1 payment
|
| Johnson & Johnson Vision Care | Acuvue | $19 | 1 payment
|
| CooperVision | Clariti Contact Lens | $19 | 1 payment
|
| Carl Zeiss Meditec | None Specified | $17 | 1 payment
|
2019: $118
| Alcon Vision | Precision 1 | $118 | 1 payment
|
Professional record
- NPI
- 1508179706
- Licence
- CA 13964California C13964: Cancelled
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 152W00000X (152W00000X)
- Mailing address
- 43955 S Moray St, Fremont, CA, 94539
- NPI first listed
- 2010-07-16
- NPI last updated
- 2019-09-03
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 5411 Thornwood Dr, San Jose, CA, 95123